TherapeuticsMD annual gross margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TherapeuticsMD's gross margin was 100.00% for fiscal 2023.
View full TherapeuticsMD company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | 100.00% | +2.00 pp |
| 2022 | 2022-12-31 | 98.00% | +52.49 pp |
| 2021 | 2021-12-31 | 45.51% | −29.86 pp |
| 2020 | 2020-12-31 | 75.37% | −11.87 pp |
| 2019 | 2019-12-31 | 87.24% | +4.24 pp |
| 2018 | 2018-12-31 | 83.00% | −1.29 pp |
| 2017 | 2017-12-31 | 84.28% | +5.91 pp |
| 2016 | 2016-12-31 | 78.38% | +0.75 pp |
| 2015 | 2015-12-31 | 77.63% | +2.06 pp |
| 2014 | 2014-12-31 | 75.56% | −2.11 pp |
| 2013 | 2013-12-31 | 77.67% | +12.98 pp |
| 2012 | 2012-12-31 | 64.69% | +10.05 pp |
| 2011 | 2011-12-31 | 54.64% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2023 | 2023-12-31 | 100.00% | +100.00 pp |
| Q2 2023 | 2023-06-30 | 100.00% | +100.00 pp |
| Q1 2023 | 2023-03-31 | 100.00% | −1982.45 pp |
| Q4 2022 | 2022-12-31 | 78.89% | −0.32 pp |
| Q3 2022 | 2022-09-30 | 0.00% | −82.04 pp |
| Q2 2022 | 2022-06-30 | 0.00% | −76.41 pp |
| Q1 2022 | 2022-03-31 | 2,082.45% | +2007.16 pp |
| Q3 2021 | 2021-09-30 | 79.21% | −3.84 pp |
| Q2 2021 | 2021-06-30 | 82.04% | +23.15 pp |
| Q1 2021 | 2021-03-31 | 76.41% | −1.43 pp |
| Q4 2020 | 2020-12-31 | 75.28% | −6.61 pp |
| Q3 2020 | 2020-09-30 | 83.05% | −10.86 pp |
| Q2 2020 | 2020-06-30 | 58.88% | −20.57 pp |
| Q1 2020 | 2020-03-31 | 77.84% | −2.83 pp |
| Q4 2019 | 2019-12-31 | 81.90% | +0.58 pp |
| Q3 2019 | 2019-09-30 | 93.91% | +14.04 pp |
| Q2 2019 | 2019-06-30 | 79.46% | −8.48 pp |
| Q1 2019 | 2019-03-31 | 80.67% | −2.54 pp |
| Q4 2018 | 2018-12-31 | 81.32% | −4.26 pp |
| Q3 2018 | 2018-09-30 | 79.87% | −4.26 pp |
| Q2 2018 | 2018-06-30 | 87.93% | +3.97 pp |
| Q1 2018 | 2018-03-31 | 83.21% | −0.24 pp |
| Q4 2017 | 2017-12-31 | 85.58% | +1.39 pp |
| Q3 2017 | 2017-09-30 | 84.14% | +6.49 pp |
| Q2 2017 | 2017-06-30 | 83.96% | +9.63 pp |
| Q1 2017 | 2017-03-31 | 83.45% | +5.93 pp |
| Q4 2016 | 2016-12-31 | 84.18% | +6.14 pp |
| Q3 2016 | 2016-09-30 | 77.65% | +0.65 pp |
| Q2 2016 | 2016-06-30 | 74.33% | −4.36 pp |
| Q1 2016 | 2016-03-31 | 77.52% | +0.84 pp |
| Q4 2015 | 2015-12-31 | 78.05% | −1.30 pp |
| Q3 2015 | 2015-09-30 | 77.00% | +2.52 pp |
| Q2 2015 | 2015-06-30 | 78.69% | +2.49 pp |
| Q1 2015 | 2015-03-31 | 76.68% | +6.03 pp |
| Q4 2014 | 2014-12-31 | 79.34% | −4.34 pp |
| Q3 2014 | 2014-09-30 | 74.47% | +2.73 pp |
| Q2 2014 | 2014-06-30 | 76.20% | −1.52 pp |
| Q1 2014 | 2014-03-31 | 70.65% | −4.61 pp |
| Q4 2013 | 2013-12-31 | 83.68% | +10.50 pp |
| Q3 2013 | 2013-09-30 | 71.74% | +1.35 pp |
| Q2 2013 | 2013-06-30 | 77.72% | +23.18 pp |
| Q1 2013 | 2013-03-31 | 75.26% | +21.83 pp |
| Q4 2012 | 2012-12-31 | 73.18% | +46.46 pp |
| Q3 2012 | 2012-09-30 | 70.39% | −14114.56 pp |
| Q2 2012 | 2012-06-30 | 54.54% | +1.56 pp |
| Q1 2012 | 2012-03-31 | 53.43% | −4.64 pp |
| Q4 2011 | 2011-12-31 | 26.72% | — |
| Q3 2011 | 2011-09-30 | 14,184.95% | — |
| Q2 2011 | 2011-06-30 | 52.99% | — |
| Q1 2011 | 2011-03-31 | 58.06% | — |
Over the last five reported fiscal years, TherapeuticsMD's gross margin increased from 83.00% to 100.00%, a change of +17.00 percentage points. The latest reported quarter, Q4 2023, shows 100.00%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TherapeuticsMD filings at SEC.gov ↗